uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences. (Hematologi)
Show others and affiliations
2006 (English)In: Haematologica, ISSN 0390-6078, E-ISSN 1592-8721, Vol. 91, no 9, 1281-2 p.Article in journal (Refereed) Published
Abstract [en]

Twenty-five patients with myeloproliferative diseases were treated with pegylated interferon alpha-2b. Prior to therapy, 15/25 patients had a JAK2(V617F) mutation. Eight JAK2-positive patients were on therapy in hematological complete remission at 24 months. Five of eight patients demonstrated a 1.2-3.6 fold reduction in the percentage of JAK2(V617F) cells.

Place, publisher, year, edition, pages
2006. Vol. 91, no 9, 1281-2 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-103899PubMedID: 16956836OAI: oai:DiVA.org:uu-103899DiVA: diva2:218959
Available from: 2009-05-25 Created: 2009-05-25 Last updated: 2010-12-15Bibliographically approved

Open Access in DiVA

No full text

By organisation
Department of Medical Sciences
In the same journal
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 135 hits
ReferencesLink to record
Permanent link

Direct link